MD by the Sea is excited to offer semaglutide medication also known as Wegovy®/Ozempic®.
Semaglutide is the active ingredient used in Wegovy®,
which is FDA-Approved for weight loss.
It is also the active ingredient in Ozempic® for diabetes. Semaglutide (or Wegovy®) is a once weekly injection that has helped people lose and maintain weight loss in combination with diet and exercise.
Semaglutide (Wegovy®/Ozempic®) is a GLP-1 agonist that promotes appetite suppression by delaying gastric emptying.
This helps to increase fullness, lower glucose and even decreases the desire for fatty and/or sugary foods.
In a recent 2021 study, non-diabetic patients reported as much as 20% weight loss.
In 2021, the results of a study with semaglutide for non-diabetic patients for weight loss were published.
More than 50% of trial participants lost 15% of their body weight, Between 33% to 40% lost 20% of their body weight.
Other benefits were noted such as decreased cardiac risk factors, decreased lipid profile, BMI, systolic blood pressure and glucose.
Semaglutide (Wegovy®/Ozempic®) is a GLP-1 agonist that promotes appetite suppression by delaying gastric emptying.
This helps to increase fullness, lower glucose and even decreases the desire for fatty and/or sugary foods.
In a recent 2021 study, non-diabetic patients reported as much as 20% weight loss.
On average patients had a weight loss of 33lbs!
In 2021, the results of a study with semaglutide for non-diabetic patients for weight loss were published.
More than 50% of trial participants lost 15% of their body weight, Between 33% to 40% lost 20% of their body weight.
Other benefits were noted such as decreased cardiac risk factors, decreased lipid profile, BMI, systolic blood pressure and glucose.
